Influenza News and Research

Latest Influenza News and Research

Gen-Probe reports total revenues of $135.4M for first-quarter 2010

Gen-Probe Incorporated today reported financial results for the first quarter of 2010, highlighted by $135.4 million of total revenues and earnings per share of $0.48 on both a non-GAAP and GAAP basis.

30 Apr 2010

Practicing NPIs may help limit transmission of pandemic flu: Study

Practicing non-pharmaceutical interventions such as hand-washing and mouth covering may help limit the transmission of the pandemic flu, but more research on these measures is critical according to a new study appearing in the May issue of AJIC: American Journal of Infection Control, the official publication of the Association for Professionals in Infection Control and Epidemiology, Inc.

30 Apr 2010

Novavax reports positive results from Phase II study of trivalent VLP influenza vaccine in older adults

Novavax, Inc. reported today that its trivalent seasonal influenza virus-like-particle (VLP)-based vaccine candidate was safe and immunogenic against the 2009-2010 seasonal influenza virus strains in older adults 60 years or higher in age.

30 Apr 2010

OMT beneficial as adjunctive treatment in elderly people with pneumonia

A clinical trial of 406 subjects 50 years of age and older who were hospitalized with pneumonia showed a one-day reduction in the length of hospital stay in those patients who received osteopathic manipulative treatment (OMT) in addition to conventional medical care when compared to patients who received only conventional medical care. A per protocol analysis also showed a significant reduction in the duration of intravenous antibiotics and in respiratory failure or death in the group that received OMT when compare to the conventional care only group.

29 Apr 2010

Adamas Pharmaceuticals presents study results of TCAD therapy in immunocompromised influenza A patients

Adamas Pharmaceuticals, Inc., a privately held company, announced today the results from the first clinical study evaluating triple combination antiviral drug (TCAD) therapy for the treatment of influenza A in immunocompromised patients. Data from this Phase 1b study were presented by clinical investigator Dr. Janet Englund in a clinical symposium at the 23rd International Conference on Antiviral Research (ICAR) in San Francisco.

29 Apr 2010

Ceregene continues enrollment in new Phase 1/2 clinical study of CERE-120 for Parkinson's disease

Ceregene, Inc., a biopharmaceutical company, announced today that enrollment is proceeding in a new Phase 1/2 clinical study evaluating CERE-120, a gene therapy product which delivers the neurotrophic factor neurturin, to dying neurons in Parkinson's disease patients. This new clinical study follows a completed Phase 2 trial and builds on experience gained in that trial, by enhancing the dosing regimen and optimizing the duration of patient follow up.

29 Apr 2010

Seasonal flu shots: Are they responsible for the adverse reactions? Investigations on

After the seasonal flu vaccines caused over 250 cases of fever, vomiting and convulsions and one reported death in under-fives there has been intense investigations to detect the cause. Further vaccinations were stopped last Friday.

28 Apr 2010

Positive results from interim analysis of ongoing Phase 2a study of BCX4208

BioCryst Pharmaceuticals, Inc. announced positive top-line results from a planned interim analysis of its ongoing Phase 2a, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of orally administered BCX4208 in patients with gout.

28 Apr 2010

Stalk structure of Mx protein restrains components of influenza virus in infected cells

When the human body becomes infected with new influenza viruses, the immune system rapidly activates an inborn protective mechanism to inhibit the intruding pathogen. A protein known as Mx plays an important role in this process, keeping the spread of viruses in check. Exactly how Mx accomplishes this task was previously unknown.

28 Apr 2010

BiondVax announces successful conclusion of second Phase I/II trial of Multimeric-001 Universal Flu Vaccine

BiondVax Pharmaceuticals Ltd., an Israeli biopharmaceutical company at the forefront of global efforts towards the development of a Universal Influenza Vaccine, announced the successful conclusion of the Company's second Phase I/II clinical trial of the Multimeric-001 Universal Influenza Vaccine.

28 Apr 2010

Discovery Labs reports first-quarter results, updates on Surfaxin and key pipeline programs

Discovery Laboratories, Inc., a biotechnology company developing its novel synthetic surfactant and aerosol technologies for respiratory diseases, today provides an update on Surfaxin® and key pipeline and business initiatives and reports financial results for the first quarter ended March 31, 2010.

28 Apr 2010

Tamiflu and two other drugs used to treat influenza appear safe for pregnant women and babies: Study

Tamiflu and two other drugs used to treat influenza appear safe for pregnant women and their babies, researchers at UT Southwestern Medical Center have found in a retrospective study of 239 cases of women who received the medications during pregnancy.

28 Apr 2010

Australian Medical Association says doctor followed all procedures in flu shot death

The death of a two year old girl a day after she relieved a flu shot has become an issue for the Brisbane doctor who gave the girl and her twin sister the flu shot. The Australian Medical Association branch in Queenland has warned against making Dr Amir Eskandari the scapegoat in the case.

27 Apr 2010

People infected with gastrointestinal worms respond better to injected vaccines

According to the World Health Organization, two billion people around the globe suffer from chronic parasitic worm infections, which, in addition to causing illness and developmental delay, are also suspected to interfere with the effectiveness of ordinary vaccines, making their victims more vulnerable to life-threatening diseases. A recent discovery by researchers at the Trudeau Institute promises to bypass these obstacles and help deliver more effective vaccines to these people, boosting their protection against common childhood diseases.

27 Apr 2010

Fears over flu jab adverse reactions in children

Till now more than 250 under five kids have developed some or other adverse reaction to seasonal flu jabs. There has been a mad rush at the adverse events hotline with many parents and healthcare staff panicking as more reports are streaming in. Initially there was a spike in cases in Western Australia but now more cases are being reported from Queensland and South Australia. The affected children developed fever, vomiting and seizures. Even New Zealand has reported three cases of febrile convulsions.

27 Apr 2010

Nanoviricides become registered trademark under USPTO

NanoViricides, Inc., announced today that the mark "nanoviricides" has now become a registered trademark under the US Patents and Trademarks Office. The mark was entered into the "principal register" of trademarks at the USPTO on April 20, 2010.

26 Apr 2010

Toddler dies after seasonal flu shot – health authorities on alert

Last Friday, Australia's Chief Medical Officer Professor Jim Bishop had announced his decision to suspend free seasonal flu vaccinations after more than 20 under-five kids mainly in Western Australia developed reactions to the shots. They developed fever, vomiting and convulsions. One of the children was reported to be severely ill.

25 Apr 2010

1976 "swine flu" vaccine protects against 2009 pandemic H1N1 influenza virus

New evidence shows immunization against "swine flu" in 1976 might provide individuals with some protection against the 2009 pandemic H1N1 influenza virus, according to new research from St. Jude investigators.

24 Apr 2010

New hopes to improve cancer diagnosis and treatment for children

Motivated clinicians and an Internet connection combined with computers and e-mail access have the power to transform pediatric cancer treatment in the most remote corners of earth, according to a St. Jude investigator writing in a recent issue of The Lancet Oncology.

24 Apr 2010

News outlets examine H1N1's impact on U.S. vaccine development plans, Mexico's handling of outbreak

"A year after the emergence of swine flu [H1N1], U.S. health authorities and laboratories say the pandemic illustrated the need for new vaccine production techniques that are faster and more reliable," Agence France-Presse writes in an article that examines the challenges associated with current vaccine development practices and plans for future development.

24 Apr 2010

Influenza News and Research

Latest Influenza News and Research

Gen-Probe reports total revenues of $135.4M for first-quarter 2010

Practicing NPIs may help limit transmission of pandemic flu: Study

Novavax reports positive results from Phase II study of trivalent VLP influenza vaccine in older adults

OMT beneficial as adjunctive treatment in elderly people with pneumonia

Adamas Pharmaceuticals presents study results of TCAD therapy in immunocompromised influenza A patients

Ceregene continues enrollment in new Phase 1/2 clinical study of CERE-120 for Parkinson's disease

Seasonal flu shots: Are they responsible for the adverse reactions? Investigations on

Positive results from interim analysis of ongoing Phase 2a study of BCX4208

Stalk structure of Mx protein restrains components of influenza virus in infected cells

BiondVax announces successful conclusion of second Phase I/II trial of Multimeric-001 Universal Flu Vaccine

Discovery Labs reports first-quarter results, updates on Surfaxin and key pipeline programs

Tamiflu and two other drugs used to treat influenza appear safe for pregnant women and babies: Study

Australian Medical Association says doctor followed all procedures in flu shot death

People infected with gastrointestinal worms respond better to injected vaccines

Fears over flu jab adverse reactions in children

Nanoviricides become registered trademark under USPTO

Toddler dies after seasonal flu shot – health authorities on alert

1976 "swine flu" vaccine protects against 2009 pandemic H1N1 influenza virus

New hopes to improve cancer diagnosis and treatment for children

News outlets examine H1N1's impact on U.S. vaccine development plans, Mexico's handling of outbreak

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Influenza News and Research

Latest Influenza News and Research

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Newsletters you may be interested in